推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-54106218，021-33363733

chinasupport@letpub.com

登录 注册 新注册优惠

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis …

[HTML] from ascopubs.orgEA Perez, EH Romond, VJ Suman… - Journal of Clinical …, 2011 - jco.ascopubs.org
Purpose Trastuzumab is a humanized monoclonal antibody against the human epidermal growth
factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated
in interim analyses of four large trials. Initial data of the combined analysis of the North ...

Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

F Li… - Science, 2011 - sciencemag.org
CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, is expressed on
antigen-presenting cells (APCs) and is essential for immune activation. Although agonistic CD40
antibodies have been developed for immunotherapy, their clinical efficacy has been ...
Cited by 1

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled …

[HTML] from thelancet.comL Gianni, U Dafni, RD Gelber, E Azambuja… - The Lancet …, 2011 - Elsevier
The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing
treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant, adjuvant
chemotherapy, or both in patients with HER2-positive early breast cancer. The primary ...
Cited by 7 - Related articles - All 7 versions

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: …

G Tang, S Shak, S Paik, SJ Anderson… - Breast cancer research …, 2011 - Springer
Abstract The Oncotype DX ® Recurrence Score® (RS) is a validated genomic predictor of outcome
and response to adjuvant chemotherapy in ER-positive breast cancer. Adjuvant! was developed
using SEER registry data and results from the Early Breast Cancer Clinical Trialists' ...
Cited by 2 - Related articles - All 4 versions

DNA Mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy

[HTML] from oxfordjournals.orgFA Sinicrope, NR Foster… - Journal of the …, 2011 - jnci.oxfordjournals.org
Methods We included stage II and III colon carcinoma patients (n = 2141) who were treated in
randomized trials of 5-FU-based adjuvant therapy. Tumors were analyzed for microsatellite instability
by polymerase chain reaction and/or for MMR protein expression by ...
Cited by 1 - Related articles - All 5 versions

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451